Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib [0.03%]
3β-羟基类固醇脱氢酶抑制剂曲洛司坦可抑制肝细胞癌生长并增强索拉非尼的抗癌活性
Jiunn-Chang Lin,Chien-Liang Liu,Yuan-Ching Chang et al.
Jiunn-Chang Lin et al.
Background Human 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) is an enzyme associated with steroidogenesis, however its' role in hepatocellular carcinoma (HCC) biology is unknown. Trilostane is an inhibitor of HSD3B1 and has been tested...
Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1 [0.03%]
通过抑制谷胱甘肽-s转移酶P1来化学预防胰腺癌
Takahiro Kogawa,Yasushi Sato,Rai Shimoyama et al.
Takahiro Kogawa et al.
Pancreatic cancer is among the most refractory malignancies with poor prognosis. Thus, preventive approaches, in addition to the development of novel therapeutic strategies are essential for this type of cancer. KRAS mutations occur very ea...
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors [0.03%]
Brentuximab Vedotin 治疗复发/难治性睾丸癌 II 期临床试验
Ryan Ashkar,Darren R Feldman,Nabil Adra et al.
Ryan Ashkar et al.
Background CD-30 is highly expressed in some patients with non-seminomatous germ-cell tumors. Brentuximab vedotin is an antibody-drug conjugate directed to CD-30. We report a phase 2 trial of brentuximab vedotin in patients with chemo-refra...
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review [0.03%]
达拉菲尼和曲美替尼治疗BRAF V600E突变非小细胞肺癌引发胃肠穿孔的病例报告及文献回顾
Yuri Shimada,Yuki Sato,Ryo Tachikawa et al.
Yuri Shimada et al.
Gastrointestinal perforation related to mitogen-activated protein kinase kinase (MEK) inhibitors has been reported previously; however, there has been no case report of such a condition in patients with non-small cell lung cancer (NSCLC). H...
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study [0.03%]
卡培他滨、伊立替康、奥沙利铂和贝伐珠单抗联合治疗转移性结直肠癌的疗效：QUATTRO-II研究的安全导入结果
Daisuke Kotani,Takayuki Yoshino,Masahito Kotaka et al.
Daisuke Kotani et al.
Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (Clinic...
Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer [0.03%]
肌动蛋白结合蛋白四肌球蛋白4在胰腺癌中的临床预后及分子免疫特征分析
Xue Zhou,Xiaowei Zhu,Junchao Yao et al.
Xue Zhou et al.
Pancreatic cancer (PC) is one of the most lethal human solid malignancies with devastating prognosis, making biomarker detection considerably important. Immune infiltrates in microenvironment is associated with patients' survival in PC. The...
Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma [0.03%]
茋类化合物通过调节组蛋白乙酰化和甲基化标记在恶性黑色素瘤中的表观遗传药物作用机制研究
Melina Mitsiogianni,Ioannis Anestopoulos,Sotiris Kyriakou et al.
Melina Mitsiogianni et al.
Melanoma is an aggressive skin cancer with increasing incidence rates globally. On the other hand, isothiocyanates are derived from cruciferous vegetables and are known to exert a wide range of anti-cancer activities including, among others...
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma [0.03%]
识别出CDC20作为与免疫浸润相关的肝癌预后生物标志物
Chen Xiong,Zhihuai Wang,Guifu Wang et al.
Chen Xiong et al.
Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. E3 ubiquitin-protein ligases play essential roles in HCC, such as regulating progression, migration, and metastasis. We aimed to explore a hub E3 ubiquitin-protein ligase...
Xiaoyu Li,Yue Yang
Xiaoyu Li
China has been criticized for the long drug delay for a long time. There was little understanding of Chinese drug lag formation from the investigational new drug (IND) submission to the new drug application (NDA) approval. Therefore, we ana...
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer [0.03%]
幽门螺旋杆菌感染可能是胃癌免疫检查点抑制剂治疗的有利因素
Ming-Jun Zhang,Dong-Sheng Chen,Si Li et al.
Ming-Jun Zhang et al.
Gastric cancer (GC) has the third highest rate of cancer incidence and mortality worldwide. First-line immune checkpoint inhibitor (ICI) therapy for advanced GC led to landmark breakthroughs, but which GC patients are most likely to benefit...